ELCC 2021 | KEYNOTE-407: pembrolizumab plus chemo improves OS and PFS in NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses updated data from the KEYNOTE-407 trial (NCT02775435) investigating first-line pembrolizumab plus chemotherapy for patients with advanced squamous non-small cell lung cancer (NSCLC). At three years of follow-up, the study reported a median overall survival (OS) of 17.2 months and an OS rate of 29.7% in the pembrolizumab plus chemotherapy arm, versus a median OS of 11.6 months and an OS rate of 18.2% in the placebo plus chemotherapy arm. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.